Premium
P2‐033: Plasma amyloid‐beta as a predictor of dementia and cognitive decline: A systematic review and meta‐analysis
Author(s) -
Koyama Alain,
Okereke Olivia,
Yang Ting,
Selkoe Dennis,
Grodstein Francine
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.923
Subject(s) - dementia , meta analysis , medicine , confidence interval , relative risk , amyloid beta , oncology , cognitive decline , disease
sex and body mass index (BMI) and also examined interaction between CVDE and each biomarker separately. Results: Mean (SD) LpPla2 was 297 (71.6) in AD cases and 281 (65.6) in controls, and mean (SD) homocysteine was 16 (9.0) in AD cases, and 13 (5.0) in controls. Both biomarkers significantly predicted case-control status in unadjusted and adjusted models (p1⁄4 0.005 for LpPla2, adjusted; p1⁄4 0.009 homocysteine, adjusted), with higher levels associated with AD. There was no significant interaction between the effects of the two biomarkers. The interaction between CVDE and LpPla2 was significant.Conclusions:LpPla2 levels were higher in AD cases compared to controls, and may be an independent risk factor for AD. Once the disease is established, the predictive value of this biomarker was independent of homocysteine levels, which were elevated in AD cases as expected. The effect of LpPla2 on differentiating cases and controls was enhanced in patients who also had cardiovascular disease or its risk factors.